Bolt Biotherapeutics Q3 EPS $(2.25) Beats $(3.69) Estimate
Benzinga Newsdesk 16 hours ago
NewsEarningsEarnings Beats
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(2.25) per share which beat the analyst consensus estimate of $(3.69) by 38.86 percent. This is a 39.52 percent increase over losses of $(3.72) per share
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(2.25) per share which beat the analyst consensus estimate of $(3.69) by 38.86 percent. This is a 39.52 percent increase over losses of $(3.72) per share from the same period last year.